OPTN Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
OptiNose, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$2.10 |
| 52 Week Low | US$0.32 |
| Beta | -0.17 |
| 1 Month Change | -12.48% |
| 3 Month Change | -41.65% |
| 1 Year Change | -64.40% |
| 3 Year Change | -75.29% |
| 5 Year Change | -95.75% |
| Change since IPO | -97.79% |
Recent News & Updates
OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31%
Nov 26
Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50
Nov 15Recent updates
OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31%
Nov 26Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50
Nov 15Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch
Sep 27Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower
Aug 11Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%
Apr 27There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump
Mar 01Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price
Dec 28OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%
May 23The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically
Mar 09OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M
Aug 11OptiNose: Potential Winner In Chronic Sinusitis Treatment
Jun 16OptiNose: Underappreciated Potential
Mar 10Shareholder Returns
| OPTN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.8% | -1.6% | -2.4% |
| 1Y | -64.4% | 7.8% | 23.3% |
Return vs Industry: OPTN underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: OPTN underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| OPTN volatility | |
|---|---|
| OPTN Average Weekly Movement | 14.4% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OPTN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OPTN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 132 | Ramy Mahmoud | www.optinose.com |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
OptiNose, Inc. Fundamentals Summary
| OPTN fundamental statistics | |
|---|---|
| Market cap | US$63.36m |
| Earnings (TTM) | -US$31.15m |
| Revenue (TTM) | US$75.67m |
0.8x
P/S Ratio-2.0x
P/E RatioIs OPTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPTN income statement (TTM) | |
|---|---|
| Revenue | US$75.67m |
| Cost of Revenue | US$7.41m |
| Gross Profit | US$68.26m |
| Other Expenses | US$99.41m |
| Earnings | -US$31.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 90.21% |
| Net Profit Margin | -41.16% |
| Debt/Equity Ratio | -306.6% |
How did OPTN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OptiNose, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| John Tanner | Cantor Fitzgerald & Co. |
| Matthew Caufield | H.C. Wainwright & Co. |